XIAP and inflammatory bowel disease: However, continuous inhibition of XIAP as a therapeutic strategy raises concerns due to the role of this protein in innate immune and cell death regulation and because the loss‐of‐function mutations of XIAP associate with hereditary very early‐onset (VEO) IBD and X‐linked lymphoproliferative disease type 2 (XLP‐2) (Rigaud et al, 2006; Damgaard et al, 2013; Speckmann et al, 2013; Latour & Aguilar, 2015).